Document Detail

Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study.
MedLine Citation:
PMID:  23378417     Owner:  NLM     Status:  Publisher    
BackgroundThe role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned. The objective of this randomized double-blinded study is to assess whether cholecalciferol therapy can increase serum 25-hydroxyvitamin D [25(OH)D] levels in haemodialysed patients and the safety implications of this therapy on certain biological parameters and vascular calcifications score.MethodsForty-three haemodialysis patients were randomized to receive placebo or cholecalciferol (25 000 IU) therapy every 2 weeks. The biological parameters, serum calcium, phosphorus, 25(OH)D and parathormone (PTH) levels, were monitored monthly for 12 consecutive months. Vascular calcifications were assessed by lateral X-ray radiography.ResultsAt baseline, the mean serum 25(OH)D levels were low and similar in both groups. Thirty patients (16 treated and 14 placebo) completed the study: 11 patients died (5 placebo and 6 treated), 1 patient dropped out and 1 patient was transplanted (both from the placebo group). After 1 year, the percentage of 25(OH)D deficient patients was significantly lower in the treated group. None of the patients developed hypercalcaemia. The PTH levels tended to increase over the study period under placebo and to decrease in the cholecalciferol group. The median changes in PTH levels from baseline to 1 year were statistically different between the two groups [+80 (-58 to 153) and -115 (-192 to 81) under placebo and cholecalciferol treatment, respectively, P = 0.02].The calcification scores increased equivalently in both groups (+2.3 per year).ConclusionsCholecalciferol is effective and safe, and does not negatively affect calcium, phosphorus, PTH levels and vascular calcifications. Additional studies are needed to compare the impacts of nutritional and active vitamin D agents on vascular calcification and mortality.
Pierre Delanaye; Laurent Weekers; Xavier Warling; Martial Moonen; Nicole Smelten; Laurent Médart; Jean-Marie Krzesinski; Etienne Cavalier
Related Documents :
23588337 - Chitosan-based dressing for the treatment of external/accessible bleedings in children ...
23075127 - Hydroxyethyl starch or saline for fluid resuscitation in intensive care.
25141107 - Cross-sectional study comparing different therapeutic modalities for cystic lymphangiom...
24597837 - The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprot...
25141907 - α1-blockers for the treatment of recurrent urinary tract infections in women with dysf...
429737 - A psychogeriatric assessment program. v. three-year follow-up.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-1
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  -     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1Nephrology-Dialysis-Transplantation, University of Liège, CHU Sart Tilman, Liège, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synergy of the antibiotic colistin with echinocandin antifungals in Candida species.
Next Document:  Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hyperten...